The Peptide Field. Thymosin alpha-1: approval and evidence record.

Editorial review: 2026-08-30. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/thymosin-alpha-1

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=thymosin-alpha-1#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: No FDA-approved thymosin alpha-1 product was identified in the United States as reviewed August 30, 2026

Exact product limits: FDA treats the free base and its acetate salt as different chemical forms. FDA's 2024 review described Zadaxin as a finished medicine with narrow approval outside the United States. The ingredient name alone does not identify that product. No FDA-approved U.S. product was found.

Human outcomes: Moderate. A large randomized sepsis study found no clear drop in 28-day deaths. FDA found that the wider disease evidence did not establish a benefit.

Body effects in people: Moderate. Studies in people measured how it moved through the body and changed blood tests tied to the immune system. These findings do not establish a general health benefit.

What the evidence shows: Sepsis is a dangerous body response to infection. The TESTS study assigned 1,106 adults with sepsis at 22 centers in China to thymosin alpha-1 or placebo by chance. A placebo looks like the study product but has no active ingredient. In the corrected analysis, 23.4% of the thymosin alpha-1 group and 24.1% of the placebo group died within 28 days. This was not a clear difference. Other randomized studies tested severe pancreas inflammation, viral liver disease, and earlier sepsis groups. Their results did not establish a broad treatment benefit.

What remains unknown: FDA reviewed proposed uses that included viral liver disease, cancer, sepsis, COVID-19, vaccine response, lung disease, and other conditions. FDA found too little reliable evidence to show that it worked for the uses it reviewed. The records do not show a general “immune boost,” infection prevention, long-COVID benefit, or anti-aging effect. They also do not show that an online or compounded product matches study material.

Safety limits: FDA says compounded thymosin alpha-1 may cause unwanted immune reactions. FDA also flags impurities and problems with confirming the active ingredient. The available data cannot define every risk. This guide gives no dosing, injection, sourcing, or treatment instructions.

Approval claim: “Thymosin alpha-1 is FDA-approved in the United States.”
Verdict: Misleading. FDA says no approved U.S. drug contains thymosin alpha-1 free base or its acetate salt. Foreign product status does not create U.S. approval.
Evidence basis: Regulatory or product record. Scope: United States regulatory status as reviewed August 30, 2026.
Claim sources: https://www.fda.gov/media/183820/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. FDA identity overview for thymosin alpha-1. 2024. Accessed 2026-08-30. https://www.fda.gov/media/183645/download

U.S. Food and Drug Administration. FDA review of the separate thymosin beta-4 fragment called TB-500. 2025. Accessed 2026-08-30. https://www.fda.gov/media/193349/download

U.S. Food and Drug Administration. FDA evaluation of thymosin alpha-1 for pharmacy compounding. 2024. Accessed 2026-08-30. https://www.fda.gov/media/183820/download

U.S. Food and Drug Administration. FDA list of substances that may present compounding safety risks. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

U.S. Food and Drug Administration. FDA drug approvals and databases. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

The BMJ. Large randomized TESTS sepsis trial. 2025. Accessed 2026-08-30. https://www.bmj.com/content/388/bmj-2024-082583

The BMJ. Correction to the TESTS sepsis trial. 2025. Accessed 2026-08-30. https://www.bmj.com/content/389/bmj.r1098

PubMed · Critical Care. TRACE trial in acute pancreatitis. 2022. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/35713670/

PubMed · Critical Care. Earlier ETASS sepsis trial. 2013. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/23327199/

PubMed · Hepatology. Randomized chronic hepatitis B trial. 1999. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/10607256/

World Anti-Doping Agency. 2026 Prohibited List. 2026. Accessed 2026-08-30. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

Keep the limits, review date, and sources with this record. Check the current source for changes.